Literature DB >> 6216809

Increased plasma catecholamine levels in patients with symptomatic mitral valve prolapse.

A Pasternac, J F Tubau, P E Puddu, R B Król, J de Champlain.   

Abstract

Total plasma catecholamine levels, plasma norepinephrine levels, heart rate, and systolic and diastolic pressures were measured in 15 symptomatic patients with mitral valve prolapse and in 19 normal subjects in supine baseline conditions and in a standing position. In the 15 symptomatic patients, total plasma catecholamine levels and plasma norepinephrine levels were significantly elevated in both positions, and heart rate was lower than in normal subjects in the supine position but returned to normal in the upright position. Thus, symptomatic patients with mitral valve prolapse demonstrate increased resting sympathetic tone. In addition, the associated supine bradycardia suggested that increased vagal tone might also be present at rest. These observations support the hypothesis of a dual autonomic dysfunction in these patients and could account for some of the clinical manifestations of the mitral valve prolapse syndrome.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6216809     DOI: 10.1016/0002-9343(82)90758-6

Source DB:  PubMed          Journal:  Am J Med        ISSN: 0002-9343            Impact factor:   4.965


  14 in total

1.  P-wave dispersion and heart rate variability in children with mitral valve prolapse.

Authors:  Kadir Babaoglu; Gürkan Altun; Köksal Binnetoğlu
Journal:  Pediatr Cardiol       Date:  2011-01-30       Impact factor: 1.655

Review 2.  Postural orthostatic tachycardia syndrome.

Authors:  A K Agarwal; R Garg; A Ritch; P Sarkar
Journal:  Postgrad Med J       Date:  2007-07       Impact factor: 2.401

3.  Posture and Gender Differentially Affect Heart Rate Variability of Symptomatic Mitral Valve Prolapse and Normal Adults.

Authors:  Chien-Jung Chang; Ya-Chu Chen; Chih-Hsien Lee; Ing-Fang Yang; Ten-Fang Yang
Journal:  Acta Cardiol Sin       Date:  2016-07       Impact factor: 2.672

4.  Haemodynamic and neurohormonal responsiveness to different stress tests in mitral valve prolapse.

Authors:  G Micieli; A Cavallini; G V Melzi d'Eril; C Tassorelli; F Barzizza; A P Verri; I Richichi; G Nappi
Journal:  Clin Auton Res       Date:  1991-12       Impact factor: 4.435

5.  Assessment of ventricular repolarization inhomogeneity in patients with mitral valve prolapse: value of T wave peak to end interval.

Authors:  Osman Can Yontar; Kemal Karaagac; Erhan Tenekecioglu; Ahmet Tutuncu; Mehmet Demir; Mehmet Melek
Journal:  Int J Clin Exp Med       Date:  2014-08-15

6.  Role of intact cardiac nerves and reflex mechanisms in desensitization to catecholamines in conscious dogs.

Authors:  J Nejima; N Uemura; D E Vatner; C J Homcy; T H Hintze; S F Vatner
Journal:  J Clin Invest       Date:  1990-12       Impact factor: 14.808

7.  ST-Segment Depression in Hyperventilation Indicates a False Positive Exercise Test in Patients with Mitral Valve Prolapse.

Authors:  Andreas P Michaelides; Charalampos I Liakos; Charalambos Antoniades; Dimitrios L Tsiachris; Dimitrios Soulis; Polichronis E Dilaveris; Konstantinos P Tsioufis; Christodoulos I Stefanadis
Journal:  Cardiol Res Pract       Date:  2010-11-14       Impact factor: 1.866

8.  Panic disorder, social anxiety disorder, and a possible medical syndrome previously linked to chromosome 13.

Authors:  Ardesheer Talati; Kathryn Ponniah; Lisa J Strug; Susan E Hodge; Abby J Fyer; Myrna M Weissman
Journal:  Biol Psychiatry       Date:  2007-10-24       Impact factor: 13.382

Review 9.  The mitral valve prolapse epidemic: fact or fiction.

Authors:  R P Lewis; C F Wooley; A J Kolibash; H Boudoulas
Journal:  Trans Am Clin Climatol Assoc       Date:  1987

10.  QT dispersion and diastolic functions in differential diagnosis of primary mitral valve prolapse and rheumatic mitral valve prolapse.

Authors:  Baris Guven; Ayse Guler Eroglu; Kadir Babaoglu; Tevfik Demir; Alper Güzeltas; Funda Oztunc; Levent Saltik
Journal:  Pediatr Cardiol       Date:  2007-10-05       Impact factor: 1.655

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.